Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

December 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Donafenib

200 mg BID,oral administration will start before the first HAIC treatment .

DRUG

Sintilimab

200 mg Q3W,Intravenous infusion will perform before HAIC treatment.

OTHER

HAIC

HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06512467 - Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter